Cromatina/Epigenética
Os inibidores de cromatina/epigenética são compostos que modulam a estrutura e função da cromatina ou interferem em modificações epigenéticas, como a metilação do DNA e a modificação de histonas. Esses inibidores são ferramentas essenciais para estudar a regulação da expressão gênica e o papel da epigenética em doenças como o câncer, distúrbios neurológicos e anomalias do desenvolvimento. Ao direcionar os processos epigenéticos, esses inibidores podem alterar os padrões de expressão gênica e oferecer novas vias terapêuticas. Na CymitQuimica, oferecemos uma ampla seleção de inibidores de cromatina/epigenética de alta qualidade para apoiar sua pesquisa em biologia molecular, genética e epigenética.
Subcategorias de "Cromatina/Epigenética"
Foram encontrados 2235 produtos de "Cromatina/Epigenética"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
PROTAC BRD9-binding moiety 1
CAS:<p>PROTAC BRD9-binding moiety 1 that binds to BRD9, and used for inhibiting BRD9 activity, based on PROTAC.</p>Fórmula:C23H25N3O7S2Pureza:98%Cor e Forma:SolidPeso molecular:519.59PROTAC BET Degrader-10
CAS:<p>PROTAC BET Degrader-10 targets and degrades BRD4 with a DC50 of 49 nM, using Cereblon ligands.</p>Fórmula:C39H39ClN8O6SCor e Forma:SolidPeso molecular:783.3MZP-54
CAS:<p>MZP-54 is a selective degrader of BRD3/4 based on PROTAC technology(Kd of 4 nM for Brd4BD2)</p>Fórmula:C55H66ClN7O9SPureza:98%Cor e Forma:SolidPeso molecular:1036.67OARV-771
CAS:<p>OARV-771: VHL-based PROTAC targeting BET; DC50: Brd4-6nM, Brd2-1nM, Brd3-4nM; enhanced cell permeability.</p>Fórmula:C49H59ClN8O8S2Cor e Forma:SolidPeso molecular:987.62MT1
CAS:<p>MT1, a bivalent chemical probe targeting BET bromodomains, demonstrates an IC50 value of 0.789 nM for BRD4(1).</p>Fórmula:C54H66Cl2N10O9S2Cor e Forma:SolidPeso molecular:1134.2PROTAC BRD4 Degrader-14
<p>PROTAC BRD4 Degrader-14 binds VHL & BRD4, degrades BRD4 in PC3 cells; IC50: 1.8/1.7 nM BD1/BD2.</p>Fórmula:C57H61F2N9O11S2Cor e Forma:SolidPeso molecular:1150.27SJ988497
CAS:<p>SJ988497: PROTAC JAK2 degrader, inhibits CRLF2r cell growth, degrades GSPT1, combines Ruxolitinib, linker, Pomalidomide; researched for ALL.</p>Fórmula:C36H36N10O5Cor e Forma:SolidPeso molecular:688.74JAK-IN-15
CAS:<p>JAK-IN-15 is a JAK inhibitor. WO2016119700A1 (Compound 15).</p>Fórmula:C22H23FN4O3SCor e Forma:SolidPeso molecular:442.51GSK3735967
CAS:<p>GSK3735967: DNMT1 inhibitor, IC50 40 nM, dicyanopyridine core, binds hemimethylated CpG, interacts with H4K20me3.</p>Fórmula:C25H31N7OSCor e Forma:SolidPeso molecular:477.62PROTAC BRD4 Degrader-13
CAS:<p>PROTAC BRD4 Degrader-13 targets VHL and BRD4, degrading BRD4 with DC50 of 0.025/6.0 nM in PC3 cells when linked to STEAP1/CLL1 antibodies.</p>Fórmula:C68H85F2N11O17P2S2Cor e Forma:SolidPeso molecular:1492.55NCT-TFP
CAS:<p>NCT-TFP is PARP probe used to identifying Poly(ADP-ribose) polymerases (PARP) inhibitors[1].</p>Fórmula:C41H34F4N2O5Cor e Forma:SolidPeso molecular:710.71MS479
<p>MS479 is a BRD4 PROTAC degrader that binds with high affinity to BRD4-BD2 and GLP (BRD4-BD2: Kd = 200 nM; GLP: Kd = 306 nM). It effectively reduces the protein levels of BRD4 short isoforms. By directly binding to its substrate GLP, MS479 recruits the E3 ligase SPOP as a bridging protein. Additionally, MS479 can be utilized to inhibit the proliferation of colorectal cancer cells.</p>Cor e Forma:Odour SolidMACTIDE-V
<p>MACTIDE-V is an orally active and selective peptide-drug conjugate targeting CD206. This compound delivers Verteporfin to CD206+ tumor-associated macrophages (TAM), thereby inhibiting the YAP/TAZ signaling pathway. It facilitates YAP exclusion from the nucleus, induces TAM polarization toward an anti-tumor phenotype, enhances phagocytosis and antigen presentation, and promotes T cell infiltration and NK cell activity. MACTIDE-V suppresses primary tumor growth and lung metastasis in triple-negative breast cancer (TNBC) mouse models.</p>Fórmula:C109H156N22O27S2Cor e Forma:SolidPeso molecular:2269.09517DAO-dBET1
<p>DAO-dBET1, a dual-action PROTAC incorporating the PROTAC degrader dBET1, effectively serves as a potent BRD4 degrader and exhibits a DC50 value of 277 nM in the presence of CoCl2. Additionally, DAO-dBET1 inhibits hypoxia and Cath-L activation with an IC50 value of 281 nM.</p>Cor e Forma:Odour SolidDelcasertib acetate
<p>Delcasertib acetate is a selective δ protein kinase C (δPKC) inhibitor for the study of acute myocardial infarction and pain.</p>Fórmula:C122H203N45O36S2Pureza:98.92%Cor e Forma:SolidPeso molecular:2940.33I-BET432
<p>I-BET432, a BET inhibitor, blocks BRD4 BD1/BD2 (pIC50: 7.5/7.2), is oral, and targets cancer/inflammation.</p>Fórmula:C18H21N3O3Cor e Forma:SolidPeso molecular:327.38Echinomycin
CAS:<p>Echinomycin (Quinomycin A) is a quinoxaline antibiotic and a DNA-intercalating peptide that inhibits hypoxia-inducible factor-1 (HIF-1) DNA binding activity.</p>Fórmula:C51H64N12O12S2Pureza:95%Cor e Forma:SolidPeso molecular:1101.26PKC β pseudosubstrate
CAS:<p>Selective cell-permeable peptide inhibitor of protein kinase C (IC50 ~ 0.5 μM).</p>Fórmula:C177H294N62O38S3Pureza:98%Cor e Forma:SolidPeso molecular:3994.84MS8511 HCl
<p>MS8511 HCl is a G9a/GLP inhibitor with anticancer activity that can be used in the study of a variety of cancers including brain cancer.</p>Fórmula:C28H42ClN5O3Pureza:98.9% - 98.96%Cor e Forma:SolidPeso molecular:532.12HDAC6-IN-53
<p>HDAC6-IN-53 (Compound W28) is an inhibitor targeting histone deacetylase 6 (HDAC6) with an IC50 of 19.65 nM. It reduces the idiopathic pulmonary fibrosis (IPF) phenotype by inhibiting TGF-β1-induced collagen expression and demonstrates therapeutic efficacy in a bleomycin-induced mouse model of pulmonary fibrosis. HDAC6-IN-53 is applicable for research in idiopathic pulmonary fibrosis and related pulmonary fibrotic diseases.</p>Cor e Forma:Odour Solid
